Professor Liu Jianping, director of the Beijing University of Chinese Medicine Center for Evidence-based Medicine and the Chinese leader of the project, introduced that the Chinese and British governments have raised the issue of how to jointly respond to global antibiotic resistance in areas of cooperation many years ago.
In 2018, the Ministry of Science and Technology of China and the Innovation Administration of the United Kingdom jointly established a cooperation project between the two governments to conduct research on antibiotic resistance, including research on antibiotic resistance in Chinese medicine. Beijing University of Chinese Medicine and the University of Southampton in the United Kingdom, which have been cooperating for more than 10 years, have jointly applied for the clinical evaluation and drug resistance research of Chinese medicine combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease, and were approved by relevant Chinese and British authorities in 2019. Project.
According to the project leader of the University of Southampton in the United Kingdom, the clinical use of traditional Chinese medicine should be combined with the conventional treatment of western medicine. The school was the first to carry out clinical research on Chinese medicine in the UK, involving Chinese herbal compound, acupuncture and other fields, and has important influence in European countries. The person in charge said: "Traditional Chinese medicine has very good advantages in anti-infection. Through the cooperation between China and the UK, scientific research will surely achieve satisfactory results."
Liu Jianping stated that TCM has theoretical experience in treating infectious diseases and infectious diseases, such as Treatise on Febrile Diseases and Febrile Diseases, as well as long-term used prescriptions, which have spread to Japan, South Korea and other countries. Tu Youyou's discovery of the antimalarial drug artemisinin and the Nobel Prize in Physiology or Medicine are the best evidence. Therefore, in dealing with antibiotic resistance, traditional Chinese medicine can firstly reduce the use of antibiotics, and secondly, the use of antibiotics may reduce the occurrence of drug resistance.
Liu Jianping introduced that the project lasted 3 years and will be completed in mid-2022. Both China and the UK will have their own achievements and outputs, and part of the research results will be shared between China and the UK, which is an important leap for Chinese medicine products to the UK and European markets.
The Ministry of Science and Technology Key Research and Development Program Sino-British Government Cooperation Project-Clinical evaluation and Drug Resistance Research Project of Chinese Medicine Combined with Antibiotics in the Treatment of Acute Exacerbation of COPD, by Beijing University of Chinese Medicine, Anhui Jiren Pharmaceutical Co., Ltd., Southampton, UK University, Phoenix Pharmaceutical Co., Ltd., adopting the 2+2 model (two scientific research institutions + two companies lead), and unite with the Institute of Chinese Materia Medica of China Academy of Chinese Medical Sciences, the First Affiliated Hospital of Anhui Medical University, the Institute of Immunochemistry of Shanghai University of Science and Technology, and Beijing Zhong Dongzhimen Hospital of Medical University jointly participates in basic and clinical research work.
The project was funded by the Ministry of Science and Technology and the British Innovation Administration respectively. The reporting agencies of China and the UK jointly participated in the joint pharmaceutical companies. It has the distinctive feature of combining production, education and research, and lays the foundation for the transformation of future research results.
Anhui Jiren Pharmaceutical Co., Ltd., which participated in the research of this project, previously used its Shufeng Jiedu Capsule with independent intellectual property rights to carry out 16 clinical and basic researches on acute exacerbation of chronic obstructive pulmonary disease, including 5 national-level topics, and published relevant basics , More than 200 clinical research papers, including 13 SCI papers. In 2014, the product won the China Patent Gold Award.